Table 3.

Baseline characteristics of populations with comparison groups

Baseline	LBBAP*		BVP
characteristics	Value	n	Value	n	P†
Mean age ± SD, years	62.88 ± 11.67	100	63.54 ± 10.07	159	0.63
Male, n (%)	54 (54.0)	79	94 (61.6)	159	0.26
Hypertension, n (%)	35 (38.9)	90	53 (41.1)	129	0.74
Diabetes mellitus, n (%)	26 (28.9)	90	34 (26.4)	129	0.68
AF, n (%)	17 (18.9)	90	23 (17.8)	129	0.83
ICM, n (%)	11 (11.0)	100	20 (12.6)	159	0.70
NICM, n (%)	89 (89.0)	100	139 (86.8)	159	0.60
Mean NYHA class ± SD	2.96 ± 0.65	100	2.95 ± 0.68	159	0.91
Mean QRSd ± SD, ms	172.08 ± 18.04	90	170.70 ± 24.03	159	0.64
Mean LVEF ± SD, %	29.71 ± 6.09	100	28.34 ± 5.53	159	0.06
Mean LVEDD ± SD, mm	66.31 ± 7.68	68	69.14 ± 6.05	105	0.01
Mean LVESV ± SD, mL	136.16 ± 50.90	40	158.63 ± 58.37	79	0.04
Mean LVEDV ± SD, mL	195.30 ± 58.42	40	220.05 ± 69.89	79	0.06
Mean LAD ± SD, mm	44.36 ± 5.99	47	46.13 ± 6.08	84	0.69
β‐blocker, n (%)	92 (92.0)	100	149 (93.7)	159	0.60
ACEi/ARB, n (%)	93 (93.0)	100	148 (93.1)	159	0.98
Diuretics, n (%)	95 (95.0)	100	158 (99.4)	159	0.02
Aldosterone antagonist, n (%)	93 (93.0)	100	147 (92.3)	159	0.83
Digoxin, n (%)	37 (63.8)	58	49 (65.3)	75	0.86

ACEi, angiotensin‐converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin II receptor blocker; BVP, biventricular pacing; ICM, ischemic cardiomyopathy; LAD, left atrial diameter; LBBAP, left bundle branch area pacing; LVEDD, left ventricular end‐diastolic diameter; LVEDV, left ventricular end‐diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end‐systolic volume; NICM, nonischemic cardiomyopathy; NYHA, New York Heart Association; QRSd, QRS duration.

^⁎LBBAP studies with comparison group.

^†Analysis of patients from studies with a comparison group of LBBAP and BVP.